The Library
Ligand-controlled reactivity and cytotoxicity of cyclometalated rhodium(III) complexes
Tools
Tools
Tools
Zhang, Wen-Ying, Bridgewater, Hannah E., Banerjee, Samya, Soldevila-Barreda, Joan J., Clarkson, Guy J., Shi, Huayun, Imberti, Cinzia and Sadler, Peter J. (2020) Ligand-controlled reactivity and cytotoxicity of cyclometalated rhodium(III) complexes. European Journal of Inorganic Chemistry, 2020 (11-12). pp. 1052-1060. doi:10.1002/ejic.201901055 ISSN 1434-1948.
|
PDF
WRAP-ligand-controlled-reactivity-cytotoxicity-cyclometalated-rhodium(III)-complexes-Sadler-2019.pdf - Accepted Version - Requires a PDF viewer. Download (1913Kb) | Preview |
Official URL: http://dx.doi.org/10.1002/ejic.201901055
Abstract
We report the synthesis, characterization and cytotoxicity of six cyclometalated rhodium(III) complexes [CpXRh(C^N)Z]0/+, in which CpX = Cp*, Cpph, or Cpbiph, C^N = benzo[h]quinoline, and Z = chloride or pyridine. Three X‐ray crystal structures showing the expected “piano‐stool” configurations have been determined. The chlorido complexes hydrolyzed faster in aqueous solution, and reacted preferentially with 9‐ethyl guanine or glutathione compared to their pyridine analogues. The 1‐biphenyl‐2,3,4,5‐tetramethylcyclopentadienyl complex [CpbiphRh(benzo‐[h]quinoline)Cl] (3a) was the most efficient catalyst in coenzyme reduced nicotinamide adenine dinucleotide (NADH) oxidation to NAD+ and induced an elevated level of reactive oxygen species (ROS) in A549 human lung cancer cells. The pyridine complex [CpbiphRh(benzo[h]quinoline)py]+ (3b) was the most potent against A549 lung and A2780 ovarian cancer cell lines, being 5‐fold more active than cisplatin towards A549 cells, and acted as a ROS scavenger. This work highlights a ligand‐controlled strategy to modulate the reactivity and cytotoxicity of cyclometalated rhodium anticancer complexes.
| Item Type: | Journal Article | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QD Chemistry Q Science > QR Microbiology R Medicine > RC Internal medicine |
||||||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Science > Chemistry | ||||||||||||
| Library of Congress Subject Headings (LCSH): | Antibody-dependent cell cytotoxicity, Rhodium, Antineoplastic agents | ||||||||||||
| Journal or Publication Title: | European Journal of Inorganic Chemistry | ||||||||||||
| Publisher: | Wiley-VCH Verlag GMBH | ||||||||||||
| ISSN: | 1434-1948 | ||||||||||||
| Official Date: | 27 March 2020 | ||||||||||||
| Dates: |
|
||||||||||||
| Volume: | 2020 | ||||||||||||
| Number: | 11-12 | ||||||||||||
| Page Range: | pp. 1052-1060 | ||||||||||||
| DOI: | 10.1002/ejic.201901055 | ||||||||||||
| Status: | Peer Reviewed | ||||||||||||
| Publication Status: | Published | ||||||||||||
| Reuse Statement (publisher, data, author rights): | This is the peer reviewed version of the following article: Zhang, W. , Bridgewater, H. E., Banerjee, S. , Soldevila‐Barreda, J. J., Clarkson, G. J., Shi, H. , Imberti, C. and Sadler, P. J. (2019), Ligand‐Controlled Reactivity and Cytotoxicity of Cyclometalated Rhodium(III) Complexes. Eur. J. Inorg. Chem.. doi:10.1002/ejic.201901055, which has been published in final form at https://doi.org/10.1002/ejic.201901055. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | ||||||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||||||
| Date of first compliant deposit: | 28 November 2019 | ||||||||||||
| Date of first compliant Open Access: | 20 November 2020 | ||||||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
